Metformin and other biguanides in oncology: advancing the research agenda.
Metformin and other biguanides in oncology: advancing the research agenda.
复制标题
DOI：
10.1158/1940-6207.capr-10-0175
复制
发表时间：
2010-09
期刊：
影响因子：
--
通讯作者：
Pollak M
中科院分区：
文献类型：
--
作者：
Pollak M
回顾性研究表明，与其他糖尿病患者相比，二甲双胍治疗的糖尿病患者的癌症负担大幅降低，这些研究可能无法前瞻性地证实。目前尚不清楚这是否反映了化学预防效应，对转化细胞的影响，或两者兼而有之。这些数据是否与非糖尿病患者相关还有待确定。然而，实验室模型为二甲双胍和其他双胍类药物在癌症治疗和化学预防中的活性提供了独立的令人印象深刻的证据。双胍机制的调查显示了相当大的复杂性，并确定了重要的知识差距，应加以解决，以确保这些药物的临床试验的最佳设计。这些试验可能定义双胍类药物预防和/或治疗许多常见癌症的重要新适应症。
Retrospective studies suggest that diabetics treated with metformin have a substantially reduced cancer burden compared with other diabetics, studies that may be impractical to confirm prospectively. It is unclear if this reflects a chemopreventive effect, an effect on transformed cells, or both. It also remains to be established if these data have relevance to people without diabetes. Laboratory models, however, provide independent impressive evidence for activity of metformin and other biguanides in both cancer treatment and chemoprevention. Investigations of biguanide mechanisms have revealed considerable complexity and have identified important gaps in knowledge that should be addressed to ensure the optimal design of clinical trials of these agents. Such trials may define important new indications of biguanides for the prevention and/or treatment of many common cancers.